People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Biotechnology, Other Health Care, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CeleCor Therapeutics, Inc. | — | Biotechnology | Series C | $71.5M | $994.8M | 2021 |
| Innovoyce LLC | — | Other Health Care | Series A | $9.9M | $97.6M | 2022 |
| Pulmoqune Therapeutics, Inc. | — | Pharma | Series A | $5.5M | $170.3M | 2020 |
Robert Hillman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Hillman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter B. Finn | 2 | 11 |
| Michael Davin | 1 | 2 |
| Jack B. Lief | 1 | 1 |
| Andreas B. Ritzi | 1 | 1 |
| Andreas S. Ritzi | 1 | 1 |
| Caspar F.V. Sturm | 1 | 1 |
| Robert S. Hillman | 1 | 1 |
| Tome Andrade | 1 | 1 |
| Steven Zeitels | 1 | 1 |
| Sarah B. Schlesinger, MD | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.